- Home
- OPI vs CYCC Comparison
OPI vs CYCC Comparison
Compare OPI & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPI
- CYCC
- Stock Information
- Founded
- OPI 2009
- CYCC 1992
- Country
- OPI United States
- CYCC Malaysia
- Employees
- OPI N/A
- CYCC N/A
- Industry
- OPI Real Estate Investment Trusts
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- OPI Real Estate
- CYCC Health Care
- Exchange
- OPI Nasdaq
- CYCC Nasdaq
- Market Cap
- OPI 16.6M
- CYCC 17.5M
- IPO Year
- OPI 2009
- CYCC N/A
- Fundamental
- Price
- OPI $0.55
- CYCC $6.37
- Analyst Decision
- OPI
- CYCC
- Analyst Count
- OPI 0
- CYCC 0
- Target Price
- OPI N/A
- CYCC N/A
- AVG Volume (30 Days)
- OPI 17.5M
- CYCC 82.6K
- Earning Date
- OPI 10-29-2025
- CYCC 11-11-2025
- Dividend Yield
- OPI 5.47%
- CYCC N/A
- EPS Growth
- OPI N/A
- CYCC N/A
- EPS
- OPI N/A
- CYCC N/A
- Revenue
- OPI $466,972,000.00
- CYCC $10,000.00
- Revenue This Year
- OPI N/A
- CYCC $137.21
- Revenue Next Year
- OPI N/A
- CYCC N/A
- P/E Ratio
- OPI N/A
- CYCC N/A
- Revenue Growth
- OPI N/A
- CYCC N/A
- 52 Week Low
- OPI $0.18
- CYCC $3.08
- 52 Week High
- OPI $2.44
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- OPI 87.83
- CYCC 37.28
- Support Level
- OPI $0.22
- CYCC $5.92
- Resistance Level
- OPI $0.23
- CYCC $8.82
- Average True Range (ATR)
- OPI 0.05
- CYCC 0.58
- MACD
- OPI 0.03
- CYCC -0.04
- Stochastic Oscillator
- OPI 61.45
- CYCC 15.52
About OPI Office Properties Income Trust of Beneficial Interest
Office Properties Income Trust is a United States-based real estate investment trust. Its property portfolio is mainly composed of single-tenant office buildings, as well as multitenant properties, which are leased to parties of high credit quality characteristics. Its major tenant is the U.S. government, followed by other smaller government entities and corporations. The company's properties are spread across the United States. The company has only one segment which is direct ownership of real estate properties.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.